By Benjamin Chiou
Date: Thursday 14 Mar 2024
(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.
Amolyt, which is a specialist in the treatment of rare endocrine disease, will be purchased for $800m upfront on completion of the...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news